Industry Notes / Pharma / Chapter 18 of 20 · Side-by-side
India mirror: the pharmacy-of-the-world ceiling
Most tablets, little of the profit pool
India
- Record ~$31 bn exports sitting in generic price deflation
- ~40% of US generic scripts supplied from India
- Structurally dependent on China for fermentation APIs (~65%+)
- Day-one machine: ~50 brands, three forms, shelf-ready overnight
Map to China
- China sema expiry will copy price collapse + volume procurement
- Weight domestic sema biosimilars near zero; pay for next-gen molecules
- “India substitution” as a threat to China API is often overstated
- China’s edge is molecule engineering, trial speed, CDMO—not generic shelf fill
FY2026 India drug exports ~$31.1 bn—about a third of Lilly’s annual sales guide. Semaglutide day-one: ~50 brands and ~80% price cuts—world-class execution, tiny value capture. China–India is upstream/downstream, not a symmetric race.
Source：Pharmexcil / NITI Aayog；司美印度专利到期公开报道（2026-03）
Research notes, not investment advice.